Led by a team of African researchers, first doses of the novel T cell-inducing GRAdHIVNE1 vaccine candidate have been given.

Jon Walsh, founder, chief scientific officer, Unlearn, explains how AI-designed therapies and digital twin technology are ...

With Human Research Ethics Committee (HREC) approval already secured, Oragenics is working closely with Southern Star to complete site selection, finalize investigator agreements, and prepare for ...

HHS says the elimination of 22 mRNA vaccine development projects for COVID-19 and bird flu signals a shift in vaccine ...

Pelage’s PP405, a first-in-class regenerative treatment, reactivates dormant stem cells to regrow hair. Phase 2a shows early, significant results.

Seventy per cent enrolment of participants for the Phase III clinical trial of the indigenous one-shot dengue vaccine, DengiAll, has been completed, Minister of State for Health, Prataprao Jadhav, ...

Nucleus Network acquires UK-based clinical trial organisation, Hammersmith Medicines Research: Brisbane, Australia Tuesday, August 5, 2025, 14:00 Hrs [IST] Nucleus Network, a glob ...

Researchers at the University of New Mexico are preparing to launch a phase 1 clinical trial for an Alzheimer's vaccine after ...

Jay Chhablani, MD, presented the phase 1/2 clinical trial data for OCU410, at the 2025 annual meeting of the American Society ...

The Company plans to extend its Phase II trial of HT-001 in Cancer Patients with skin toxicities in European Union (EU) Countries NEW YORK, July 29, 2025 /PRNewswire/ ...

Study results support advancing SGX945 in this difficult to treat orphan disease PRINCETON, N.J., July 31, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company) ...

Cardiol Therapeutics reports topline results from phase II ARCHER trial of CardiolRx in acute myocarditis patients: Toronto, Ontario Friday, August 8, 2025, 12:00 Hrs [IST] Cardio ...